Table 5. Treatment Outcomes by... | American Society of Hematology

Table 5.

Treatment Outcomes by Expression of Multidrug Resistance Proteins MDR1, LRP, and MRP, CsA-Inhibited Functional Efflux, and CD34 Among 352 AML Patients

	No. of Patients	Complete Remission (CR)			Resistant Disease (RD)			OS			RFS
	No. of Patients	% CR	95% CI (%)	P	% RD	95% CI (%)	P	OS at 4 yr (%)	95% CI (%)	P	RFS at 4 yr (%)	95% CI (%)	P
MDR1 (MRK16)
Bright	64	48	36-61	.012^5-150	36	24-48	.0007^5-150	20	10-30	.47	23	8-37	.77^5-150
Moderate	35	46	29-62		37	21-53		6	0-13		6	0-18
Dim	24	63	43-82		25	8-42		17	3-30		20	0-40
Negative	228	54	47-60		23	18-29		18	13-23		17	10-24
MDR1 (MM4.17)
Bright	89	44	34-54	.039^5-150	36	26-46	.0092^5-150	17	9-25	.47	23	10-36	.86^5-150
Moderate	37	65	49-80		22	8-35		11	2-20		8	0-19
Dim	25	44	25-63		40	21-59		28	10-46		36	8-65
Negative	200	56	49-62		23	17-28		17	12-22		15	8-22
LRP56
Positive	138	50	42-58	.50^5-150	25	18-33	.53^5-150	17	11-23	.53	21	11-30	.92^5-150
Negative	180	53	46-61		29	22-36		16	11-22		15	8-23
MRP1
Positive	32	56	39-73	.93^5-150	19	5-32	.55^5-150	13	2-23	.58	11	0-26	.43^5-150
Negative	289	52	46-58		28	23-34		17	13-21		17	11-23
CsA-inhibited Di(OC)₂efflux
Bright	87	39	29-49	.039^5-150	39	29-49		13	6-20	.45^5-150	18	5-30	.93^5-150
Moderate	43	67	53-81		23	11-36		23	11-36		28	11-44
Dim	12	50	22-78		50	22-78		8	0-24		17	0-46
Negative	172	55	47-62		22	15-28		16	10-21		12	5-18
CsA-inhibited Rh123 efflux
Bright	70	37	26-48	.028^5-150	41	30-53	.0036^5-150	13	5-21	.36	23	7-39	.83^5-150
Moderate	39	62	46-77		26	12-39		15	4-27		13	0-26
Dim	12	58	30-86		25	1-49		33	7-60		43	6-80
Negative	197	55	48-62		23	16-30		16	11-21		15	8-22
CD34
Pos (total)	134	51	43-60	.92^5-151	33	25-41	.16^5-151	18	11-24	.79^5-151	19	9-28	.94^5-151
Pos (sub)	70	54	43-66		24	14-34		16	7-24		21	8-34
Weak/Neg	147	53	45-61		23	16-30		17	11-23		14	7-22

	No. of Patients	Complete Remission (CR)			Resistant Disease (RD)			OS			RFS
	No. of Patients	% CR	95% CI (%)	P	% RD	95% CI (%)	P	OS at 4 yr (%)	95% CI (%)	P	RFS at 4 yr (%)	95% CI (%)	P
MDR1 (MRK16)
Bright	64	48	36-61	.012^5-150	36	24-48	.0007^5-150	20	10-30	.47	23	8-37	.77^5-150
Moderate	35	46	29-62		37	21-53		6	0-13		6	0-18
Dim	24	63	43-82		25	8-42		17	3-30		20	0-40
Negative	228	54	47-60		23	18-29		18	13-23		17	10-24
MDR1 (MM4.17)
Bright	89	44	34-54	.039^5-150	36	26-46	.0092^5-150	17	9-25	.47	23	10-36	.86^5-150
Moderate	37	65	49-80		22	8-35		11	2-20		8	0-19
Dim	25	44	25-63		40	21-59		28	10-46		36	8-65
Negative	200	56	49-62		23	17-28		17	12-22		15	8-22
LRP56
Positive	138	50	42-58	.50^5-150	25	18-33	.53^5-150	17	11-23	.53	21	11-30	.92^5-150
Negative	180	53	46-61		29	22-36		16	11-22		15	8-23
MRP1
Positive	32	56	39-73	.93^5-150	19	5-32	.55^5-150	13	2-23	.58	11	0-26	.43^5-150
Negative	289	52	46-58		28	23-34		17	13-21		17	11-23
CsA-inhibited Di(OC)₂efflux
Bright	87	39	29-49	.039^5-150	39	29-49		13	6-20	.45^5-150	18	5-30	.93^5-150
Moderate	43	67	53-81		23	11-36		23	11-36		28	11-44
Dim	12	50	22-78		50	22-78		8	0-24		17	0-46
Negative	172	55	47-62		22	15-28		16	10-21		12	5-18
CsA-inhibited Rh123 efflux
Bright	70	37	26-48	.028^5-150	41	30-53	.0036^5-150	13	5-21	.36	23	7-39	.83^5-150
Moderate	39	62	46-77		26	12-39		15	4-27		13	0-26
Dim	12	58	30-86		25	1-49		33	7-60		43	6-80
Negative	197	55	48-62		23	16-30		16	11-21		15	8-22
CD34
Pos (total)	134	51	43-60	.92^5-151	33	25-41	.16^5-151	18	11-24	.79^5-151	19	9-28	.94^5-151
Pos (sub)	70	54	43-66		24	14-34		16	7-24		21	8-34
Weak/Neg	147	53	45-61		23	16-30		17	11-23		14	7-22

F5-150

Two-tailed P value from simple logistic (CR, RD) or proportional hazards (OS, RFS) regression analysis with multidrug resistance or efflux treated as a quantitative variable.

F5-151

P value for heterogeneity among the 3 indicated CD34 groups based on simple logistic (CR, RD) or proportional hazards (OS, RFS) regression analysis.

View Large

This Feature Is Available To Subscribers Only